● Recruiting

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Condition: Peripheral T Cell Lymphoma · Relapsed Peripheral T-Cell Lymphoma · Refractory T-Cell Lymphoma · Sponsor: The First Affiliated Hospital of Xiamen University

PhasePhase 2

Planned participants33

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

To determine the efficacy and safety of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.

This description comes directly from the study's public registry record.

Talk to the study team

Bing Xu · +8618750918842 · xubingzhangjian@126.com

Zhifeng Li · +8613606901162 · lzf_xm@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated Hosptial of Xiamen University

Xiamen, Fujian, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06151106